Jens Rengelshausen

<i>CYP2C19</i> Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

Magdalena Maria ten Hoevel, Jürgen Burhenne, I. Walter‐Sack et al. · The Journal of Clinical Pharmacology · 2008 · 198 citations

Molecular Pharmacology, Voriconazole Exposure, Major Factor +15

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

Gerd Mikus, V SCHOWEL, Malgorzata Drzewinska et al. · Clinical Pharmacology & Therapeutics · 2006 · 154 citations

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction

Jens Rengelshausen, Christoph Göggelmann, Jürgen Burhenne et al. · British Journal of Clinical Pharmacology · 2003 · 144 citations · Full text

Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics

Jens Rengelshausen, Maria Josefine Banfield, K. Riedel et al. · Clinical Pharmacology & Therapeutics · 2005 · 139 citations

Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine

Germain Mandi, Boubacar Coulibaly, Steffen Witte et al. · Malaria Journal · 2006 · 121 citations · Full text